

Stefan Kasper

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5242553/publications.pdf>

Version: 2024-02-01

122
papers

9,052
citations

136950

32
h-index

42399

92
g-index

132
all docs

132
docs citations

132
times ranked

12782
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. <i>New England Journal of Medicine</i> , 2016, 375, 1856-1867.	27.0	3,845
2	Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. <i>Lancet</i> , The, 2019, 393, 1948-1957.	13.7	1,494
3	Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. <i>Oral Oncology</i> , 2018, 81, 45-51.	1.5	589
4	Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1104-1115.	10.7	325
5	Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. <i>Blood</i> , 2006, 107, 293-300.	1.4	252
6	Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 323-335.	10.7	173
7	Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. <i>International Clinical Psychopharmacology</i> , 2001, 16, 75-86.	1.7	147
8	Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas. <i>Journal of Clinical Oncology</i> , 2019, 37, 2507-2507.	1.6	113
9	The IL-33/ST2 pathway shapes the regulatory T cell phenotype to promote intestinal cancer. <i>Mucosal Immunology</i> , 2019, 12, 990-1003.	6.0	107
10	A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML. <i>Blood</i> , 2009, 113, 4063-4073.	1.4	106
11	Stabilization of Physical RAF/14-3-3 Interaction by Cotylenin A as Treatment Strategy for RAS Mutant Cancers. <i>ACS Chemical Biology</i> , 2013, 8, 1869-1875.	3.4	105
12	Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). <i>Blood</i> , 2005, 105, 335-340.	1.4	97
13	Transient Ablation of Regulatory T cells Improves Antitumor Immunity in Colitis-Associated Colon Cancer. <i>Cancer Research</i> , 2014, 74, 4258-4269.	0.9	84
14	CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. <i>Oncologist</i> , 2018, 23, 1079-1082.	3.7	70
15	Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies. <i>Blood Cancer Journal</i> , 2012, 2, e60-e60.	6.2	68
16	Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. <i>Cancer</i> , 2019, 125, 3208-3218.	4.1	64
17	High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 54-64.	1.1	62
18	Effective open-label treatment of Tourette's disorder with olanzapine. <i>International Clinical Psychopharmacology</i> , 2000, 15, 23-28.	1.7	61

#	ARTICLE	IF	CITATIONS
19	MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy. <i>Clinical Lung Cancer</i> , 2018, 19, e441-e463.	2.6	61
20	PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer—a randomised biomarker-driven clinical phase II AIO study. <i>European Journal of Cancer</i> , 2018, 92, 11-19.	2.8	55
21	A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease. <i>International Clinical Psychopharmacology</i> , 2001, 16, 253-263.	1.7	54
22	Fatigue, barriers to physical activity and predictors for motivation to exercise in advanced Cancer patients. <i>BMC Palliative Care</i> , 2020, 19, 43.	1.8	54
23	Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder. <i>International Clinical Psychopharmacology</i> , 2001, 16, 357-361.	1.7	52
24	Development of a Highly Sensitive and Specific Method for Detection of Circulating Tumor Cells Harboring Somatic Mutations in Non-Small-Cell Lung Cancer Patients. <i>PLoS ONE</i> , 2014, 9, e85350.	2.5	51
25	Targeted therapies in gastroesophageal cancer. <i>European Journal of Cancer</i> , 2014, 50, 1247-1258.	2.8	45
26	LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 1176-1184.	4.1	44
27	Risperidone for Tourette's syndrome. <i>Lancet, The</i> , 1994, 344, 1577-1578.	13.7	43
28	Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity. <i>Cell Death and Disease</i> , 2014, 5, e1568-e1568.	6.3	42
29	Impact of RAS mutation subtype on clinical outcome—a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer. <i>Oncogene</i> , 2019, 38, 2953-2966.	5.9	38
30	In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C. <i>Leukemia</i> , 2003, 17, 999-1009.	7.2	36
31	Treatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: A biomarker analysis and updated clinical outcomes. <i>Annals of Oncology</i> , 2017, 28, v372-v373.	1.2	35
32	Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 795-805.	2.5	34
33	β-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancer. <i>British Journal of Cancer</i> , 2012, 107, 823-830.	6.4	33
34	Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade. <i>Oncogene</i> , 2013, 32, 2873-2881.	5.9	32
35	Further evaluations of nivolumab (nivo) versus investigator's choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6009-6009.	1.6	32
36	Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center. <i>European Journal of Cancer</i> , 2013, 49, 3076-3082.	2.8	26

#	ARTICLE	IF	CITATIONS
37	The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukemia. <i>Leukemia Research</i> , 2008, 32, 1698-1708.	0.8	24
38	Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy. <i>Cell Death and Disease</i> , 2014, 5, e1091-e1091.	6.3	24
39	Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression. <i>Nature Communications</i> , 2017, 8, 14447.	12.8	22
40	Nivolumab (Nivo) vs investigator's choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): Outcomes in first-line (1L) R/m patients and updated safety and efficacy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6019-6019.	1.6	20
41	Natural language processing of German clinical colorectal cancer notes for guideline-based treatment evaluation. <i>International Journal of Medical Informatics</i> , 2019, 127, 141-146.	3.3	19
42	Abstract CT099: Nivolumab (nivo) vs investigator's choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141. <i>Cancer Research</i> , 2016, 76, CT099-CT099.	0.9	18
43	Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141. <i>Oncologist</i> , 2022, 27, e194-e198.	3.7	18
44	HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas. <i>Lung Cancer</i> , 2015, 88, 34-41.	2.0	17
45	Combined systemic inflammation score (SIS) correlates with prognosis in patients with advanced pancreatic cancer receiving palliative chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 579-591.	2.5	17
46	GPR15 Facilitates Recruitment of Regulatory T Cells to Promote Colorectal Cancer. <i>Cancer Research</i> , 2021, 81, 2970-2982.	0.9	17
47	LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases—a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial. <i>BMC Cancer</i> , 2012, 12, 144.	2.6	16
48	Protein γ A immunoadsorption therapy for refractory, mitomycin γ C-associated thrombotic microangiopathy. <i>Transfusion</i> , 2007, 47, 1263-1267.	1.6	14
49	Cross-Inhibition of Interferon-Induced Signals by GM-CSF Through a Block in Stat1 Activation. <i>Journal of Interferon and Cytokine Research</i> , 2007, 27, 947-960.	1.2	13
50	Phosphorylation of p70 Ribosomal Protein S6 Kinase $\hat{2}$ -1 is an Independent Prognostic Parameter in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, e331-e352.	2.3	13
51	Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer. <i>BMC Cancer</i> , 2018, 18, 1124.	2.6	13
52	A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment. <i>Investigational New Drugs</i> , 2020, 38, 1774-1783.	2.6	13
53	Abstract CT021: Tumor-associated immune cell PD-L1 expression and peripheral immune profiling: Analyses from CheckMate 141. <i>Cancer Research</i> , 2017, 77, CT021-CT021.	0.9	13
54	Topiramate as a mood stabilizer. <i>International Clinical Psychopharmacology</i> , 2001, 16, 295-298.	1.7	12

#	ARTICLE	IF	CITATIONS
55	Molecular dissection of effector mechanisms of <i>RAS</i> -mediated resistance to anti-EGFR antibody therapy. <i>Oncotarget</i> , 2017, 8, 45898-45917.	1.8	12
56	Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1317.	0.8	11
57	Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC). <i>Oncimmunology</i> , 2020, 9, 1806680.	4.6	11
58	Long-term Survival after resection for perihilar cholangiocarcinoma: Impact of UICC staging and surgical procedure. <i>Turkish Journal of Gastroenterology</i> , 2019, 30, 454-460.	1.1	11
59	A genome-wide RNAi screen identifies proteins modulating aberrant FLT3-ITD signaling. <i>Leukemia</i> , 2013, 27, 2301-2310.	7.2	8
60	Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2021, 144, 291-301.	2.8	8
61	Panitumumab in combination with gemcitabine/cisplatin (GemCis) for patients with advanced <i>kRAS</i> WT biliary tract cancer: A randomized phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).. <i>Journal of Clinical Oncology</i> , 2015, 33, 4082-4082.	1.6	8
62	ARTHROPATHIES AND SCHIZOPHRENIA. <i>Lancet</i> , The, 1980, 316, 536-537.	13.7	7
63	Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536. <i>Oncology Research and Treatment</i> , 2017, 40, 435-439.	1.2	7
64	Mapping Patient Data to Colorectal Cancer Clinical Algorithms for Personalized Guideline-Based Treatment. <i>Applied Clinical Informatics</i> , 2020, 11, 200-209.	1.7	7
65	Photochemical internalization and gemcitabine combined with first-line chemotherapy in perihilar cholangiocarcinoma: observations in three patients. <i>Endoscopy International Open</i> , 2020, 08, E1878-E1883.	1.8	7
66	Characterization of potential predictive biomarkers of response to nivolumab in CheckMate 141 in patients with squamous cell carcinoma of the head and neck (SCCHN).. <i>Journal of Clinical Oncology</i> , 2017, 35, 6050-6050.	1.6	7
67	Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 545-554.	2.5	6
68	Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 445-455.	2.5	6
69	Abstract CT157: Treatment beyond progression with nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck in the phase 3 Checkmate 141 study. , 2017, , .		6
70	PET-directed combined modality therapy for gastroesophageal junction cancer: First results of the prospective MEMORI trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4018-4018.	1.6	6
71	Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (<scp>LICC</scp>, <scp>CELIM</scp>, <scp>FIRE</scp>â€³). <i>International Journal of Cancer</i> , 2022, 150, 1341-1349.	5.1	6
72	Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial. <i>Clinical Colorectal Cancer</i> , 2020, 19, 236-247.e6.	2.3	5

#	ARTICLE	IF	CITATIONS
73	Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP. <i>British Journal of Cancer</i> , 2021, 124, 721-727.	6.4	5
74	Dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus: mature results of a phase I/II trial. <i>Radiation Oncology</i> , 2021, 16, 59.	2.7	4
75	Abstract CT116: Nivolumab (Nivo) vs investigator's choice (IC) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): 2-yr outcomes in the overall population and PD-L1 subgroups of CheckMate 141. <i>Cancer Research</i> , 2018, 78, CT116-CT116.	0.9	4
76	Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 81-88.	2.5	3
77	Changes in fatigue, barriers, and predictors towards physical activity in advanced cancer patients over a period of 12 months—a comparative study. <i>Supportive Care in Cancer</i> , 2021, 29, 5127-5137.	2.2	3
78	Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab. <i>Frontiers in Oncology</i> , 2021, 11, 635096.	2.8	3
79	P.6.078 Personality traits in affective disorders as hints to biological disturbances. <i>European Neuropsychopharmacology</i> , 1997, 7, S288.	0.7	2
80	Comparison of the sixth and the seventh editions of the UICC classification for intrahepatic cholangiocarcinoma. <i>European Journal of Medical Research</i> , 2018, 23, 29.	2.2	2
81	Noninferiority on overall survival of every-2-weeks vs weekly schedule of cetuximab for first-line treatment of RAS wild-type metastatic colorectal cancer. <i>Annals of Oncology</i> , 2019, 30, v220-v221.	1.2	2
82	Post-hoc analyses of a subgroup of patients with advanced biliary tract cancer (BTC) who crossed over to treatment with etoposide toniribate (EDO-S7.1) in a randomized phase II study. <i>Annals of Oncology</i> , 2019, 30, v278.	1.2	2
83	Antitumor immune response is associated with favorable survival in GEP-NEN G3. <i>Endocrine-Related Cancer</i> , 2021, 28, 683-693.	3.1	2
84	Paclitaxel/carboplatin with or without cetuximab for treatment of carcinoma with unknown primary (PACET-CUP): Results of a multi-center randomized phase II AIO trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 4120-4120.	1.6	2
85	Randomized phase II study of maintenance treatment with 5-FU/FA plus panitumumab vs 5-FU/FA alone after induction (mFOLFOX6 plus panitumumab) in patients with RAS WT metastatic colorectal cancer. <i>Annals of Oncology</i> , 2016, 27, vi205.	1.2	1
86	Cetuximab biweekly (q2w) plus mFOLFOX6 as 1st line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC) — Primary endpoint and subgroup analysis of the CEBIFOX trial. <i>Annals of Oncology</i> , 2016, 27, vi167.	1.2	1
87	Phase I clinical study with photochemical internalisation, a novel technology for treatment of perihilar cholangiocarcinoma. <i>Journal of Hepatology</i> , 2017, 66, S452.	3.7	1
88	Nivolumab vs investigator's choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): treatment effect on clinical outcomes by best overall response in checkmate 141. <i>Annals of Oncology</i> , 2017, 28, v377-v378.	1.2	1
89	A biomarker combination indicating resistance to FOLFOX plus bevacizumab in metastatic colorectal cancer: Results of phase I of the PERMAD trial. <i>Annals of Oncology</i> , 2019, 30, v219-v220.	1.2	1
90	The JAK2 Kinase Inhibitor LS104 Induces Growth-Arrest and Apoptosis in JAK2V617F Positive Cells. <i>Blood</i> , 2007, 110, 3544-3544.	1.4	1

#	ARTICLE	IF	CITATIONS
91	Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1): A randomized, multidisciplinary, multinational phase III trial.. Journal of Clinical Oncology, 2015, 33, TPS4140-TPS4140.	1.6	1
92	A phase IIb study of ramucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic, chemotherapy refractory colorectal cancer patients: The RAMTAS trial of the German AIO (KRK-0316).. Journal of Clinical Oncology, 2019, 37, TPS3617-TPS3617.	1.6	1
93	Survival after secondary liver resection in metastatic colorectal cancer: A comparative analysis of the LICC trial with historical controls (CELIM, FIRE-3).. Journal of Clinical Oncology, 2019, 37, 571-571.	1.6	1
94	Molecular dissection of effector mechanisms of RAS-induced resistance to monoclonal anti-EGFR antibodies.. Journal of Clinical Oncology, 2012, 30, 501-501.	1.6	1
95	Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) (exon Tj ETQq1 1 0.784314 rgBT Journal of Clinical Oncology, 2015, 33, 3568-3568.	1.6	1
96	Characterization of potential predictive biomarkers of response to nivolumab in CheckMate-141 in patients with squamous cell carcinoma of the head and neck (SCCHN).. Journal of Clinical Oncology, 2017, 35, 5-5.	1.6	1
97	Risperidone in the treatment of Gilles de la Tourette Syndrome. European Neuropsychopharmacology, 1996, 6, S4-163.	0.7	0
98	P.6.079 Risperidone in Gilles de la Tourette syndrome patients unresponsive to typical neuroleptics. European Neuropsychopharmacology, 1997, 7, S288.	0.7	0
99	P.6.083 Enhanced striatal dopamine transporter activity in drug naive and previously treated patients with gilles de la tourette syndrome (GTS): A [123I]- ¹²⁵ I-CIT SPECT-study. European Neuropsychopharmacology, 1997, 7, S289-S290.	0.7	0
100	P01.104 Relation of suicidal behaviour, central serotonergic system and temperament and character inventory. European Psychiatry, 2000, 15, 347s-348s.	0.2	0
101	P1310 : Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1) a randomized, multidisciplinary, multinational phase III trial. Journal of Hepatology, 2015, 62, S845.	3.7	0
102	PhotoChemical internalization of gemcitabine followed by gemcitabine/cisplatin in perihilar cholangiocarcinoma: Results from a phase I dose escalation trial. Annals of Oncology, 2018, 29, viii259-viii260.	1.2	0
103	A novel biomarker combination and its association with resistance to chemotherapy combinations with bevacizumab: First results of the PERMAD trial. Annals of Oncology, 2018, 29, viii159.	1.2	0
104	Serotonin-selektive Antidepressiva(SSRI, DSA). , 2002, , 223-363.		0
105	Simultaneous protection against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR-signaling blockade by oncogenic RAS.. Journal of Clinical Oncology, 2011, 29, 440-440.	1.6	0
106	P4-07-05: Comparison of PIK3CA Hot Spot Mutations in the Primary Tumor or Metastases with PIK3CA Mutations or PIK3CA Over-Expression in Circulating Tumor Cells of Metastatic Breast Cancer Patients under Sequential Palliative Therapy.. , 2011, , .		0
107	A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial of L-BLP25 in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy.. Journal of Clinical Oncology, 2012, 30, TPS3641-TPS3641.	1.6	0
108	Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC): An interim analysis of the CEBIFOX trial.. Journal of Clinical Oncology, 2013, 31, e14502-e14502.	1.6	0

#	ARTICLE	IF	CITATIONS
109	A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial of immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy.. Journal of Clinical Oncology, 2013, 31, TPS3124-TPS3124.	1.6	0
110	Current Status of Immunotherapy in Gastroesophageal Cancer. , 2014, , 179-191.		0
111	A randomized, double-blind, placebo-controlled, multicenter, binational, phase II trial of immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy.. Journal of Clinical Oncology, 2014, 32, TPS3658-TPS3658.	1.6	0
112	Differences in gene-expression in mCRC tissue samples with regard to tumor location and used chemotherapeutic substances: Data of the FIRE-1 study.. Journal of Clinical Oncology, 2016, 34, 562-562.	1.6	0
113	Randomized, multicenter phase II trial of CAP7.1 in patients with advanced biliary tract cancers.. Journal of Clinical Oncology, 2016, 34, 441-441.	1.6	0
114	Population pharmacokinetics of CAP7.1 and the effect on total target lesion size in adult patients with biliary tract cancer.. Journal of Clinical Oncology, 2016, 34, e15602-e15602.	1.6	0
115	Kopf-Hals-Tumoren beim alten und geriatrischen Patienten. , 2017, , 1-11.		0
116	Kopf-Hals-Tumoren beim alten und geriatrischen Patienten. , 2018, , 299-309.		0
117	A novel biomarker combination and its association with resistance to chemotherapy combinations with bevacizumab: First results of the PERMAD trial.. Journal of Clinical Oncology, 2018, 36, e15545-e15545.	1.6	0
118	Randomized phase II trial of the carboxylesterase (CES)-converted novel drug EDO-S7.1 in patients (pts) with advanced biliary tract cancers (BTC).. Journal of Clinical Oncology, 2019, 37, 264-264.	1.6	0
119	A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy (LICC): Final results.. Journal of Clinical Oncology, 2019, 37, 480-480.	1.6	0
120	Survival after primary liver resection in metastatic colorectal cancer: A comparative analysis of the LICC trial with historical controls (FFCD ACHBTH AURC 9002 trial and EORTC Intergroup trial 40983).. Journal of Clinical Oncology, 2019, 37, e15019-e15019.	1.6	0
121	A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy (LICC): Final results.. Journal of Clinical Oncology, 2019, 37, 3537-3537.	1.6	0
122	Survival after secondary liver resection in metastatic colorectal cancer: A comparative analysis of the LICC trial with historical controls (CELIM, FIRE-3).. Journal of Clinical Oncology, 2019, 37, e15025-e15025.	1.6	0